Human hepatocyte transplantation corrects the inherited metabolic liver disorder arginase deficiency in mice

Stephanie A.K. Angarita, Brian Truong, Suhail Khoja, Matthew Nitzahn, Abha K. Rajbhandari, Irina Zhuravka, Sergio Duarte, Michael G. Lin, Alex K. Lam, Stephen D. Cederbaum, Gerald S. Lipshutz

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


The transplantation, engraftment, and expansion of primary hepatocytes have the potential to be an effective therapy for metabolic disorders of the liver including those of nitrogen metabolism. To date, such methods for the treatment of urea cycle disorders in murine models has only been minimally explored. Arginase deficiency, an inherited disorder of nitrogen metabolism that presents in the first two years of life, has the potential to be treated by such methods. To explore the potential of this approach, we mated the conditional arginase deficient mouse with a mouse model deficient in fumarylacetoacetate hydrolase (FAH) and with Rag2 and IL2-Rγ mutations to give a selective advantage to transplanted (normal) human hepatocytes. On day −1, a uroplasminogen-expressing adenoviral vector was administered intravenously followed the next day with the transplantation of 1 × 10 6 human hepatocytes (or vehicle alone) by intrasplenic injection. As the initial number of administered hepatocytes would be too low to prevent hepatotoxicity-induced mortality, NTBC cycling was performed to allow for hepatocyte expansion and repopulation. While all control mice died, all except one human hepatocyte transplanted mice survived. Four months after hepatocyte transplantation, 2 × 10 11 genome copies of AAV-TBG-Cre recombinase was administered IV to disrupt endogenous hepatic arginase expression. While all control mice died within the first month, human hepatocyte transplanted mice did well. Ammonia and amino acids, analyzed in both groups before and after disruption of endogenous arginase expression, while well-controlled in the transplanted group, were markedly abnormal in the controls. Ammonium challenging further demonstrated the durability and functionality of the human repopulated liver. In conclusion, these studies demonstrate that human hepatocyte repopulation in the murine liver can result in effective treatment of arginase deficiency.

Original languageEnglish
Pages (from-to)114-123
Number of pages10
JournalMolecular Genetics and Metabolism
Issue number2
StatePublished - Jun 2018
Externally publishedYes


  • Ammonia
  • Arginase deficiency
  • Cellular transplant
  • Hyperargininemia
  • Treatment
  • Urea cycle disorder


Dive into the research topics of 'Human hepatocyte transplantation corrects the inherited metabolic liver disorder arginase deficiency in mice'. Together they form a unique fingerprint.

Cite this